Get the Stockscreener App
2.25
6.13%
0.13
After Hours:
2.33
0.08
+3.56%
Okyo Pharma Limited stock is traded at $2.25, with a volume of 58,826.
It is up +6.13% in the last 24 hours and up +17.80% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$2.12
Open:
$2.24
24h Volume:
58,826
Relative Volume:
0.39
Market Cap:
$84.62M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-13.72
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+8.70%
1M Performance:
+17.80%
6M Performance:
-20.21%
1Y Performance:
+92.41%
1-Day Range:
$2.12
$2.30
1-Week Range:
$2.01
$2.4817
52-Week Range:
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.25 | 79.73M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com
OKYO Pharma appoints Robert Dempsey as new CEO By Investing.com - Investing.com Nigeria
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential - TipRanks
OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO - Proactive financial news
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO - Proactive financial news
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - BioSpace
OKYO Pharma names Robert J. Dempsey as chief executive officer By Investing.com - Investing.com Australia
OKYO Pharma names Robert J. Dempsey as chief executive officer - Investing.com
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase - TipRanks
OKYO Pharma names ophthalmology veteran Robert J Dempsey as CEO to drive next growth phase - MSN
Is Alico Inc stock a smart buy before Fed meetingRisk Management & Fast Exit and Entry Trade Guides - moha.gov.vn
Will OKYO Pharma Limited stock remain a Wall Street favoriteTrendline Breakouts & Free High Yield Portfolio Picks - bollywoodhelpline.com
Technical Analysis: What dividend safety score for OKYO Pharma Limited stockMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
OKYO Pharma reports positive phase 2 results for Urcosimod in neuropathic corneal pain - MSN
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
Will OKYO Pharma Limited stock maintain dividend yieldJuly 2025 Catalysts & Trade Opportunity Analysis Reports - Улправда
Volatility Watch: How OKYO Pharma Limited OK11 stock gains from tech spendingJuly 2025 Price Swings & Verified High Yield Trade Plans - moha.gov.vn
Bank Watch: What Wall Street predicts for OKYO Pharma Limited stock priceJuly 2025 Levels & Daily Chart Pattern Signals - Улправда
Will OKYO Pharma Limited (OK11) stock hit analyst forecastsMarket Trend Review & Weekly High Return Stock Opportunities - Улправда
Is OKYO Pharma Limited stock affected by interest rate hikesTake Profit & AI Powered Market Trend Analysis - Улправда
Will OKYO Pharma Limited stock see PE expansionJuly 2025 Reactions & Stock Market Timing Techniques - Улправда
Small cap wrap: Gunnison Copper, OKYO Pharma, Abacus Global Management… - Proactive Investors
Is OKYO Pharma Limited (OK11) stock suitable for passive index fundsJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - Улправда
OKYO Pharma management to ring Nasdaq opening bell in New York - Investing.com Australia
Pullback Watch: Why retail investors pile into OKYO Pharma Limited stock2025 Market WrapUp & AI Driven Stock Movement Reports - DonanımHaber
OKYO Pharma Ltd Rings the Nasdaq Stock Market Opening Bell - Nasdaq
OKYO Pharma Ltd Rings the Opening Bell - Nasdaq
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors
OKYO Pharma management to ring Nasdaq opening bell in New York By Investing.com - Investing.com South Africa
OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data - TipRanks
Will OKYO Pharma Limited stock outperform growth indexesPortfolio Risk Report & High Conviction Trade Alerts - DonanımHaber
OKYO Pharma to Ring the Opening Bell at Nasdaq - The Manila Times
How OKYO Pharma Limited (OK11) stock gains from tech spendingMarket Performance Summary & Expert Verified Stock Movement Alerts - DonanımHaber
Why OKYO Pharma Limited stock is rated strong buy2025 Growth vs Value & Comprehensive Market Scan Insights - DonanımHaber
Is OKYO Pharma Limited stock trading at a premium valuationPortfolio Risk Summary & Detailed Earnings Play Alerts - Улправда
Will OKYO Pharma Limited stock deliver long term returnsBreakout Watch & High Conviction Investment Ideas - Улправда
Is OKYO Pharma Limited stock positioned for digital transformation2025 Retail Activity & Precise Swing Trade Alerts - Улправда
OKYO Pharma reports favorable phase 2 data for NCP asset - Eyes On Eyecare
Okyo Pharma executive chairman increases stake in company By Investing.com - Investing.com Australia
Okyo Pharma executive chairman increases stake in company - Investing.com India
Okyo Pharma chairman acquires 24,551 company shares - TipRanks
Panetta Partners increases stake in OKYO Pharma with new share purchase - Investing.com Canada
Check out OKYO Pharma Ltd's stock price (OKYO) in real time - CNBC
Panetta Partners increases stake in OKYO Pharma with new share purchase By Investing.com - Investing.com South Africa
OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials - TipRanks
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):